Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn ...

Pfizer stock is a deep-value kind of blue chip with a yield of more than 7%. The dividend looks safe — for now. The real question is whether there’s enough growth and innovation in the pipeline as the ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...